Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.47 |
| ▸ | FNTB | P49356 | 6/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2550236 | 1.00 | FNTA (0.47) | FNTAFNTBPGGT1BLMNAFOLH1 | |
| SCHEMBL13093527 | 1.00 | FNTA (0.47) | FNTAFNTBPGGT1BLMNAFOLH1 | |
| SCHEMBL31174313 | 1.00 | FNTA (0.47) | FNTAFNTBPGGT1BLMNAFOLH1 | |
| SCHEMBL15010752 | 1.00 | FNTA (0.47) | FNTAFNTBPGGT1BLMNAFOLH1 | |
| SCHEMBL31720914 | 0.91 | ECE1 (0.43) | FNTAFNTBPGGT1BLMNALTA4H | |
| SCHEMBL9828832 | 0.89 | FNTA (0.48) | FNTAFNTBPGGT1BLMNAFOLH1 | |
| SCHEMBL2547678 | 0.89 | FNTA (0.48) | FNTAFNTBPGGT1BLMNAFOLH1 | |
| SCHEMBL31345597 | 0.89 | FNTA (0.48) | FNTAFNTBPGGT1BLMNAFOLH1 | |
| SCHEMBL30051639 | 0.86 | FNTA (0.47) | FNTAFNTBPGGT1BLMNA | |
| SCHEMBL3101246 | 0.85 | FNTA (0.50) | FNTAFNTBPGGT1BLMNAFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263437-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | claimed |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2023-03-30 | — | — | US | claimed |
| CN-114805489-A | Polypeptide for repairing skin injury or mucous membrane injury and application thereof | 四川好医生攀西药业有限责任公司 | 2022-07-29 | — | — | CN | claimed |
| WO-2022148289-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | 四川好医生攀西药业有限责任公司 | 2022-07-14 | — | — | WO | claimed |
| WO-2020071258-A1 | PROTEIN GLYCATION SUPPRESSANT | 味の素株式会社 | 2020-04-09 | — | — | WO | claimed |
| US-20260035410-A1 | THERAPEUTIC PEPTIDES AND METHODS OF PEPTIDE DESIGN | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250263437-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | disclosed |
| US-20250076302-A1 | DETECTING THE PRESENCE OF URINARY STONE DISEASE USING A PLURALITY OF URINARY METABOLITES | THE CLEVELAND CLINIC FOUNDATION | 2025-03-06 | — | — | US | disclosed |
| CN-118813574-A | Application of directional mutation glycosyltransferase in synthesis of galactoside anthocyanin | 浙江大学 | 2024-10-22 | — | — | CN | disclosed |
| CN-118496381-A | Chimeric antigen receptor polypeptide, nucleic acid, vector, lentivirus for simultaneously expressing mbIL-15 cytokine and CXCR5 chemokine receptor and application | 天津市第一中心医院 | 2024-08-16 | — | — | CN | disclosed |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| CN-114805489-A | Polypeptide for repairing skin injury or mucous membrane injury and application thereof | 四川好医生攀西药业有限责任公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20140343865-A1 | Biomarkers for Kidney Cancer and Methods Using the Same | METABOLON, INC. | 2014-11-20 | — | — | US | disclosed |
| EP-2788763-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013086365-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20110262962-A1 | METHOD FOR PRODUCING PEPTIDES | AJINOMOTO CO., INC. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20070292916-A1 | MUTANT PROTEIN HAVING THE PEPTIDE-SYNTHESIZING ACTIVITY | AJINOMOTO CO., INC. (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1829968-A1 | MUTANT PROTEIN HAVING PEPTIDE-PRODUCTION ACTIVITY | Ajinomoto Co., Inc. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070190602-A1 | Mutant protein having the peptide-synthesizing activity | AJINOMOTO CO., INC (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20060188976-A1 | Mutant protein having the peptide-synthesizing activity | AJINOMOTO CO. INC (JP) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | GABBR2, GABRB1, GABRB2 | FNTA 3505/4885FNTB 3093/4885PGGT1B 657/4885 |
| US-20260035410-A1 | THERAPEUTIC PEPTIDES AND METHODS OF PEPTIDE DESIGN | MICA, IGSF11, TNFSF10 | FNTA 3547/4885FNTB 2531/4885PGGT1B 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.